Effectiveness of an angiotensin II receptor blocker losartan as monoand combined therapy in hypertensive patients with various levels of renin-angiotensin-aldosterone system activity

Effectiveness of an angiotensin II receptor blocker losartan as monoand combined therapy in hypertensive patients with various levels of renin-angiotensin-aldosterone system activity

Aim. To study the role of angiotensin II receptor blockers (ARB), in particular, losartan, in mono- and combined therapy of patients with arterial hypertension (AH) and various renin-angiotensin profiles. To identify the patients with maximal effectiveness of antihypertensive treatment and maximal i...

Full description

Bibliographic Details
Main Authors:	Sh. V. Akhadov, G. R. Ruzbanova, G. S. Molchanova, S. N. Khoreva
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2011-02-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	артериальная гипертензия ренин альдостерон лозартан
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1459

Similar Items

Arterial hypertension progression and changing activity of reninangiotensin-aldosterone and sympatho-adrenal systems
by: Sh. V. Akhadov, et al.
Published: (2010-04-01)

Показатели вариабельности ритма сердца, активности ренина и содержания альдостерона в плазме крови при ренопаренхиматозной артериальной гипертензии
by: Н. Ю. Боровкова, et al.
Published: (2011-04-01)

Comparative effectiveness of original and generic losartan in patients with arterial hypertension
by: S. V. Nedogoda, et al.
Published: (2007-12-01)

Losartan therapy in gout patients
by: A. I. Ilyina, et al.
Published: (2008-04-01)

Renin-angiotensin-aldosterone system in climacteric women with arterial hypertension. Antihypertensive therapy features
by: A. E. Bragina, et al.
Published: (2005-12-01)

Comparing recommended doses of angiotensin receptor blockers and ACE inhibitors (CORD Study)
by: J. Spinar, et al.
Published: (2009-08-01)

RENIN AND ALDOSTERONE PRODUCTION IN CHILDREN WITH HYDRONEPHROSIS WITH RELATION TO THE SEVERITY OF NON-DIFFERENTIATED CONNECTIVE TISSUE DYSPLASIA AND TIME OF URINAL OBSTRUCTION ELIMINATION
by: A.M. Mambetova, et al.
Published: (2011-11-01)

INFLUENCE OF COMORBIDITIES ON BLOOD ALDOSTERONE LEVEL IN CHRONIC HEART FAILURE WITH PRESERVED SYSTOLIC FUNCTION OF THE LEFT VENTRICLE
by: N. T. Vatutin, et al.
Published: (2017-12-01)

Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension
by: S. V. Nedogoda, et al.
Published: (2011-12-01)

EFFICACY OF A FIXED COMBINATION OF LOSARTAN AND AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION: SEASONAL FEATURES
by: M. D. Smirnova, et al.
Published: (2017-06-01)

ALDOSTERONE AND OBESITY: WHERE TO LOOK FOR THE KEY TO THERAPY?
by: N. T. Vatutin, et al.
Published: (2016-08-01)

Angiotensin II receptor antagonist and ACE inhibitor effectiveness in cognitive function correction among elderly patients with arterial hypertension
by: S. V. Nedogoda, et al.
Published: (2007-06-01)

Losartan in postmenopausal women with essential arterial hypertension
by: O. N. Tkacheva, et al.
Published: (2010-12-01)

Primary idiopathic hyperaldosteronism in clinical practice
Published: (2012-12-01)

Use of angiotensin receptor blockers in cardiovascular protection. Current evidence and future directions
by: M. A. Munger
Published: (1970-01-01)

Pharmacogenetic aspects of eprosartan therapy and polymorphic markers of renin-angiotensin-aldosterone system genes in Uzbek patients with essential arterial hypertension
by: D. R. Kurbanova, et al.
Published: (2009-06-01)

Heart and pulmonary artery remodeling association with various levels of natriuretic peptides and renin-angiotensin-aldosterone system activation in patients with pulmonary hypertension of various etiology
by: Yu. A. Andreeva, et al.
Published: (2008-12-01)

PRIMARY HYPERALDOSTERONISM: A LONG ROAD TO DIAGNOSTICS AND EFFECTIVE TREATMENT (CLINICAL CASE)
by: Евгения Петровна Каширина, et al.
Published: (2023-08-01)

Losartan effectiveness in arterial hypertension patients (ELLA study)
by: I. E. Chazova, et al.
Published: (2007-04-01)

Distribution of genotypes and alleles of the aldosterone-synthase gene in patients with abdominal obesity
by: D. L. Brovin, et al.
Published: (2015-06-01)

The role of aldosterone in the development of atrial fibrillation: modern understanding of problem
by: N. T. Vatutin, et al.
Published: (2019-03-01)

Angiotensin II receptor antagonists – we have moved closer to the patient
by: L. G. Ratova, et al.
Published: (2005-04-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
by: M. L. Maksimov, et al.
Published: (2010-04-01)

TARGET LEVELS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM COMPONENTS AND THEIR ROLE IN CARDIOVASCULAR EVENT DEVELOPMENT AMONG PATIENTS WITH ARTERIAL HYPERTENSION
by: Sh. V. Akhadov, et al.
Published: (2009-06-01)

Left ventricular hypertrophy: renin4angiotensin system role
by: F. T. Ageev, et al.
Published: (2008-04-01)

RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND REPLICATIVE CELLULAR SENESCENCE: THEIR INTERACTION DURING THE VASCULAR AGEING
by: V. S. Pykhtina, et al.
Published: (2015-09-01)

СARDIOPROTECTION IN PATIENTS WITH HYPERTENSION – THE ROLE OF LOSARTAN
by: I. I. Chukaeva, et al.
Published: (2015-09-01)

Renin-angiotensin system blockers: therapy of choice in patients with arterial hypertension and heart failure
by: G. N. Gorokhovskaya, et al.
Published: (2013-12-01)

THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
by: N. T. Vatutin, et al.
Published: (2019-07-01)

Vitamin D role in arterial hypertension development
by: E. N. Dudinskaya, et al.
Published: (2012-06-01)

Primary aldosteronism: current diagnostic approach
by: Elena S. Eniseeva
Published: (2022-12-01)

Influence of losartan on structural and functional remodelling of cardiovascular system in comorbidity of chronic obstructive lung disease and arterial hypertension
by: V. A. Nikitin, et al.
Published: (2016-10-01)

Патогенез артериальной гипертензии (Лекция)
by: Дмитрий Игоревич Василевский, et al.
Published: (2020-12-01)

Place of renin-angiotensin-aldosterone system inhibitors and statins in the treatment of cardiovascular patients in the context of COVID-19 pandemic
by: E. V. Sayutina, et al.
Published: (2022-03-01)

Correction of hyperuricemia in metabolic syndrome
by: S. V. Nedogoda, et al.
Published: (2014-12-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
by: V. V. Fomin
Published: (2013-08-01)

RENIN-ANGIOTENSIN PROFILE AND COMPARATIVE EFFECTIVENESS OF FIRST-LINE MEDICATIONS IN MONOTHERAPY OF ESSENTIAL ARTERIAL HYPERTENSION
by: Sh. V. Akhadov, et al.
Published: (2010-06-01)

Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system
by: L. M. Resnick, et al.
Published: (2011-12-01)

Arterial hypertension and coronary heart disease: the place of angiotensin II receptor antagonists
by: E. O. Taratukhin
Published: (2012-12-01)

Comparative effects of renin-angiotensin-aldosterone system modulators on right heart function and prognosis in patients with severe systolic chronic heart failure
by: K. G. Adamyan, et al.
Published: (2012-12-01)